Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06011954
Other study ID # 7465-PV-0001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2023
Est. completion date July 31, 2027

Study information

Verified date May 2024
Source Astellas Pharma Inc
Contact Astellas Pharma Global Development, Inc.
Phone 800-888-7704
Email astellas.registration@astellas.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer. People in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed PADCEV Injection and other medicines to treat their cancer. People in the study will be treated according to their clinic's standard practice. This study is about collecting information only. This study will survey people who know they are receiving PADCEV Injection. The aims of the study are to check outcomes of treatment with PADCEV and record any medical problems during the study. Once a doctor has prescribed PADCEV Injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. During this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. If a person in the study stops taking PADCEV Injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of PADCEV Injection or until they start a different medicine for their cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 235
Est. completion date July 31, 2027
Est. primary completion date July 31, 2027
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients who receive treatment with PADCEV Injection, according to the approved local label. Exclusion Criteria: - Patients with any contraindication for PADCEV Injection, according to the approved local label. - Patients who receive or are going to receive any investigational medicine during the observation period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Enfortumab Vedotin
Intravenous

Locations

Country Name City State
Korea, Republic of Site KR82001 Seoul
Korea, Republic of Site KR82002 Seoul
Korea, Republic of Site KR82003 Seoul
Korea, Republic of Site KR82004 Seoul
Korea, Republic of Site KR82005 Seoul
Korea, Republic of Site KR82006 Seoul
Korea, Republic of Site KR82007 Seoul
Korea, Republic of Site KR82008 Seoul
Korea, Republic of Site KR82009 Seoul
Korea, Republic of Site KR82010 Seoul
Korea, Republic of Site KR82011 Seoul
Korea, Republic of Site KR82013 Seoul

Sponsors (2)

Lead Sponsor Collaborator
Astellas Pharma Korea, Inc. Seagen Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with an Adverse Event Adverse events (AEs) will be summarized using MedDRA. An AE is defined as any untoward medical occurrence in a subject administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. Up to 48 weeks after the first administration of PADCEV
Primary Number of patients with an adverse drug reaction (ADR) An ADR is defined as any noxious and unintended response associated with the use of a drug in humans, at any dose, where a causal relationship is at least a reasonable possibility. Up to 48 weeks after the first administration of PADCEV
Primary Number of patients with a serious AE (SAE) An AE is considered "serious" if it results in death or is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is a medically important event or reaction. Up to 48 weeks after the first administration of PADCEV
Primary Number of patients with a serious ADR (SADR) An ADR is considered "serious" if it results in death or is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is a medically important event or reaction. Up to 48 weeks after the first administration of PADCEV
Primary Number of patients with an unexpected AE (UAE) An UAE is an AE that the nature or severity of which is not consistent with the information in the approved Korean label. Up to 48 weeks after the first administration of PADCEV
Primary Number of patients with an unexpected ADR (UADR) An UADR is defined as an unexpected adverse drug reaction. Up to 48 weeks after the first administration of PADCEV
Primary Number of patients with an important risk An important risk is classified as an important identified risk and an important potential risk.
An identified risk is defined as the risk that correspond to undesirable clinical outcomes, with sufficient scientific evidence that the undesirable clinical outcome is caused by the drug."Important Identified Risks" are identified risks that have the potential to affect the risk-benefit balance of a product.
An potential risk is defined as the risk that correspond to undesirable clinical outcomes, with some, but not sufficient, evidence to estimate that the undesirable clinical outcome is caused by the drug."Important Potential Risks" are potential risks that have the potential to affect the risk-benefit balance of a product.
Up to 48 weeks after the first administration of PADCEV
Secondary Overall survival Overall survival (OS) is defined as time from start of PADCEV to death. Up to 48 weeks after the first administration of PADCEV
Secondary Progression free survival Progression free survival (PFS) is defined as time from start of PADCEV to progressive disease (PD) or death from any cause, whichever occurs first. Up to 48 weeks after the first administration of PADCEV
See also
  Status Clinical Trial Phase
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Terminated NCT01663285 - Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) Phase 2
Recruiting NCT00872495 - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Terminated NCT04629339 - Study of INCB086550 in Select Solid Tumors Phase 2
Recruiting NCT04114136 - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Phase 2
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Terminated NCT04501094 - A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma Phase 2
Recruiting NCT04923178 - A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Completed NCT02256436 - A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Phase 3
Terminated NCT00995488 - Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer Phase 2
Completed NCT01206426 - Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
Active, not recruiting NCT03425201 - Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) Phase 1/Phase 2
Active, not recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04180371 - Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression Phase 1/Phase 2
Active, not recruiting NCT02891161 - Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Phase 1/Phase 2
Withdrawn NCT01700010 - Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer Phase 2
Active, not recruiting NCT02516241 - Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Phase 3
Active, not recruiting NCT04152018 - Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Phase 1